Quantcast
Last updated on April 24, 2014 at 5:50 EDT

Latest Pharmaceutical companies Stories

shutterstock_101520898
2012-08-07 20:35:06

Michael Harper for redOrbit.com - Your Universe Online After another failed high-profile clinical trial, pharmaceutical companies Pfiizer Inc and Johnson & Johnson have said they´ve halted research and development of bapineuzumab, a drug which could have been used in patients with mild to moderate Alzheimer's disease. According to Reuters, both drug makers have said they´ll discontinue their studies of bapineuzumab in its intravenous (IV) form. Two late stage trials and...

2012-08-07 10:25:35

BURLINGTON, Mass., Aug. 7, 2012 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today that leaders from four inVentiv Health companies were included in PharmaVOICE's 2012 list of the "100 Most Inspiring People" in the life sciences industry. inVentiv honorees include Marianne Eisenmann, Kelly Gratz, Leigh Householder and Todd LaRoche. Every year, the July/August issue of PharmaVOICE features 100...

2012-08-07 02:29:29

SOLANA BEACH, Calif., Aug. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (OTC Markets Group: IMMY), a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has created a Science and Regulatory Advisory Board and that Dr. Gerald Yakatan has become the inaugural member of the newly created board. The Imprimis Science and Regulatory Advisory Board will be comprised of scientists and pharmaceutical industry thought leaders...

2012-08-07 02:28:40

PITTSBURGH, Aug. 7, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg, the generic version of Merck's Singulair® Tablets. Mylan also received final FDA approval for its ANDA for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Merck's Singulair®...

2012-08-06 02:25:55

MONMOUTH JUNCTION, N.J., Aug. 6, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the election of Al Altomari to its Board of Directors, effective immediately. Insmed's Board of Directors now consists of seven members, five of whom are non-executives. "Al brings to our Board nearly 30 years of valuable experience in the pharmaceutical industry, including more...

2012-08-05 23:00:52

The Pharmaceutical Product Manufacturing industry in Australia is expected to continue its gradual transformation process in view of slight revenue growth, declining research and development productivity, increasing competitive pressures and rising safety concerns. Continued global industry rationalisation may also have implications for the level of pharmaceutical manufacturing and R&D undertaken in Australia. For these reasons, industry research firm IBISWorld has updated its report on...

2012-08-03 14:22:49

XIANYANG, China, Aug. 3, 2012 /PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on July 30, 2012, after a thorough inspection of raw materials used in every production category, it received "green-light" approval from Xianyang State Food and Drug Administration (SFDA) authorities to...

2012-08-03 10:21:33

PARIS and TARRYTOWN, N.Y., Aug. 3, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP(®) (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen....

2012-08-02 10:28:29

BALA CYNWYD, Pa., Aug. 2, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against Bayer AG ("Bayer") (XETRA- BAYN.DE) and Barr Laboratories, Inc. ("Barr"") on behalf of individuals that suffered an adverse side effect while taking Yaz or Yasmin, and their generic version Ocella, such as blood clots, deep vein thrombosis, strokes, or a heart attacks. Bayer has announced that it has reached agreements to settle cases with a total...

2012-08-02 10:28:14

PARSIPPANY, N.J., Aug. 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today applauded the publication of the fourth annual Generic Pharmaceutical Association (GPhA) Generic Drug Savings Study demonstrating that the generic pharmaceutical industry has saved the U.S. healthcare system more than $1 trillion in the last decade. The study is available on the GPhA website: www.gphaonline.org. The study, based on an independent analysis of data by IMS Health -- the world's leading...